11 studies with available HRs and their 95% CIs for OS have been included in the meta-analysis, with a total of 3175 CLL patients, 346 patients were mutant SF3B1 and other 2829 patients were wild-type SF3B1. For the existence of a significant heterogeneity(I2=79.3%, P<0.001), random effects model were used in the analysis. The gene discussed is SF3B1; the disease is B-cell chronic lymphocytic leukemia.